Phanes Therapeutics
PrivateLast Round
Series B
May 25, 2021
Total Funding Raised
$40M
Company Overview
Phanes Therapeutics operates in Healthcare & Life Sciences and is based in San Diego, California. Its latest recorded funding round was a Series B round in May 2021.
Phanes Therapeutics is a biotechnology company specializing in drug discovery and early development in immuno-oncology, creating native IgG-like bispecific antibodies that improve drug-like properties to facilitate patient access to innovative therapies.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
Phanes Therapeutics Comparables
Compare Phanes Therapeutics with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Chimagen Biosciences | 84% | |
| Qure Biotechnology (Shanghai) Co., Ltd. | 78% | |
| APITBIO, Inc. | 77% |
For institutional investors. Book with your work email.
Phanes Therapeutics Funding Rounds
Historical fundraising activity
| Round | Date | Amount Raised | Valuation | Investors | Sources |
|---|---|---|---|---|---|
| Series B | May 25, 2021 | ||||
| Series A | Nov 1, 2018 |
For institutional investors. Book with your work email.
Phanes Therapeutics Investors
Notable investors and investment history
| Investor | Rounds |
|---|---|
| DYEE Capital | Series B |
| 险峰K2VC | Series B, Series A |
| Delos Capital Partners | Series B, Series A |
| Volcanics Venture | Series B, Series A |
| HongShan Capital Group (HSG) | Series A, Series B |
Market signals
Structured signals derived from secondary market and firmographic data.
- Apr 22, 2026
Updated Phase 2 results for spevatamig to be presented at ASCO Annual Meeting.
- Mar 18, 2026
Presenting three clinical posters at AACR 2026.
For institutional investors. Book with your work email.
Recent news
Latest coverage and updates
- is_developingAug 18, 2026
Phanes Therapeutics, Inc. is developing spevatamig, an investigational CLDN18.2 x CD47 bispecific antibody, as a potential first-line treatment for metastatic pancreatic ductal adenocarcinoma in the United States, with the therapy evaluated in the Phase I/II TWINPEAK study and topline Phase II results expected by the end of 2026.
- is_developingAug 17, 2026
Phanes Therapeutics, Inc. is developing spevatamig with pembrolizumab under a clinical collaboration entered in 2023 to study the combination, with the collaboration expanded to frontline biliary tract cancer.
For institutional investors. Book with your work email.
Phanes Therapeutics Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about Phanes Therapeutics's valuation, stock price, and market status.
Is Phanes Therapeutics a public or private company?
Phanes Therapeutics is a private company.
What is the current stock price of Phanes Therapeutics?
Phanes Therapeutics is a private company, so its shares have no public market price. Caplight tracks Phanes Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is Phanes Therapeutics worth (valuation)?
Valuation information for Phanes Therapeutics is not publicly available.
Can I buy Phanes Therapeutics stock?
Phanes Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was Phanes Therapeutics's last funding round?
Phanes Therapeutics's most recent funding round was Series B on May 25, 2021.
Who are the main investors in Phanes Therapeutics?
Key investors in Phanes Therapeutics include 险峰K2VC, HongShan Capital Group (HSG).
Will Phanes Therapeutics IPO soon?
No public IPO plans have been announced for Phanes Therapeutics.
How can I track Phanes Therapeutics secondary market activity?
Caplight tracks bids, offers, and trades in Phanes Therapeutics's shares on secondary markets.